%0 Figure %A Jun, Baek Gyu %A Lee, Woong Cheul %A Jang, Jae Young %A Jeong, Soung Won %A Chang, Young %A Lee, Sae Hwan %A Kim, Young don %A Kim, Sang Gyune %A Cheon, Gab Jin %A Kim, Young Seok %A Kim, Hong Soo %A Jin, So Young %D 2020 %T Recurrence rates according to FGFR2 grade, modified UICC, VEGF, TRAIL receptor 1, TRAIL receptor 2, and E-S grade. %U https://plos.figshare.com/articles/figure/Recurrence_rates_according_to_FGFR2_grade_modified_UICC_VEGF_TRAIL_receptor_1_TRAIL_receptor_2_and_E-S_grade_/11625669 %R 10.1371/journal.pone.0227440.g004 %2 https://plos.figshare.com/ndownloader/files/21072699 %K International Cancer Control %K HCC recurrence %K fibroblast growth factor receptor 2 expression %K fibroblast growth factor receptor 2 %K E-S grade %K hepatocellular carcinoma recurrence %K HCC patients %K Conclusions High FGFR 2 expression %K liver resection Background Hepatocellular carcinoma %K UICC %K 5- year recurrence rates %K FGFR 2 expression %K liver resection %K SD %K tumor-necrosis-factor-related apoptosis-inducing ligand receptors 1 %X

Kaplan-Meier estimates of (A) FGFR2, (B) modified UICC, (C) VEGF, (D) TARIL-R1, (E) TRAIL-R2, and (F) E-S grade designated as low (or early) or high (or advanced). (A) Increased FGFR2 expression was associated with recurrence. There were no significant differences in recurrence rates related to (B) modified UICC, (C) VEGF, and (E) TRAIL-R2. There was tendency toward high recurrence rate related to (D) low TRAIL-R1, difference not statistically significant. P-values were obtained from the log-rank test.

%I PLOS ONE